Goldman Sachs, New Oriental Education & Technology And Other Big Stocks Moving Lower On Tuesday
U.S. stocks traded lower, with the Dow Jones dropping around 300 points on Tuesday. Here are some big stocks recording losses in today’s session.
Why iQIYI Stock Is Nosediving
iQIYI Inc - ADR (NASDAQ: IQ) shares are trading lower by 12.78% to $5.84 during Tuesday's trading session after the company announced a proposed offering of 76.5 million American Depositary Shares, priced at $5.90 per share.
Goldman Sachs Maintains Neutral on iQIYI, Raises Price Target to $4.9
Goldman Sachs analyst Lincoln Kong maintains iQIYI (NASDAQ:IQ) with a Neutral and raises the price target from $4.4 to $4.9.
12 Communication Services Stocks Moving In Friday’s Intraday Session
Gainers World Wrestling Enter (NYSE:WWE) shares moved upwards by 20.7% to $86.93 during Friday’s regular session. The current…
Why iQIYI Shares Are Rising Today
iQIYI Inc - ADR (NASDAQ: IQ) shares are trading higher by 11.51% to $6.92 Thursday.
10 Communication Services Stocks Moving In Friday’s Pre-Market Session
Gainers National CineMedia (NASDAQ:NCMI) shares increased by 13.5% to $0.27 during Friday’s pre-market session. The company’s market cap…
Dow Rises Over 1%; Cal-Maine Foods Shares Plummet
U.S. stocks traded higher toward the end of trading, with the Nasdaq Composite climbing around 250 points on Thursday.
Why Hoth Therapeutics Shares Are Trading Higher By More Than 130%? Here Are 60 Stocks Moving In Thursday’s Mid-Day Session
Gainers
Hoth Therapeutics, Inc. (NASDAQ: HOTH) shares jumped 131.5% to $10.19 after the FDA accepted the IND application for HT-001.
China’s IQIYI Revealed Latest Metaverse Offering
Chinese video streaming platform IQIYI, Inc's (NASDAQ: IQ) extended reality (XR) business showcased the first headset of a new product line, incorporating elements of augmented, virtual, and mixed reality technology.
Why Shares Of Chinese Companies Are Trading Lower? Here Are 54 Stocks Moving In Wednesday’s Mid-Day Session
Gainers
Kala Pharmaceuticals, Inc. (NASDAQ: KALA) shares gained 130.5% to $9.03 after the company announced FDA acceptance of a IND application for its KPI-012 for the treatment of persistent corneal epithelial defect.